1. Hepatitis-2015 Orlando, USA July 20 - 22 2015
Parveen Malhotra

2. Epidemiological Profile Of Patients At a New Hub Of Hepatitis C in India
Dr. PARVEEN MALHOTRA
MD,DNB (GASTRO),MNAMS,FIACM,FICP,PGDD
PROFESSOR & HEAD
DEPTT. OF MEDICAL GASTROENTEROLOGY
PGIMS, ROHTAK

3. THE CULPRIT- NO VACCINATION

4. REAL CAUSE FOR FIGHT

5. Sources of Infection for Persons with Hepatitis C
Sexual 15%
Transfusion 10%
(before screening)
*Nosocomial;
Health-care work;
Perinatal
Other* 5%
Injecting
drug use 60%
Unknown 10%
Source: Sentinel Counties, CDC
Source: Centers for Disease Control and Prevention

6. Indian Scenario
Nearly 12.5 million Indians are suffering from Hepatitis C affecting the liver.
Over one lakh people get infected every year in India, according to the Indian National Association for the Study of Liver (INASL) study.
Every 15th carrier of the HCV is an Indian, according to a recent report and it is responsible for as many as one in four cases of liver cancer and chronic liver disease.

7. HARYANA SCENARIO
Initially in Haryana , the prevalence of Chronic hepatitis C was thought to be comparable to other parts of India.
Now the prevalence has drastically increased and is reaching the levels of areas with high incidence like Manipur and Punjab.
There are certain districts like Jind , Kaithal, Fatehabad, Panipat, Karnal and Sonepat where Prevalence is touching even 40-50%.

8. GOOD NEWS FOR HARYANA
Haryana has become the first state of India where a separate, dedicated centre has been started under Department of Medical Gastroenterology, PGIMS, Rohtak.
Free treatment of Chronic Hepatitis C has been started for patients belonging to BPL/SC and at subsidized rates for general population.
 Twenty thousand patients have been screened over different parts of haryana.

10. HEALTH TALKS

11. HEALTH LECTURES

13. MEDIA INTERACTIONS

14. BILONA VILLAGE

15. AWARENESS TALK AT DERAS

16. DHABI TEK SINGH VILLAGE

17. Patients were treated with standard doses of Pegylated Interferon and Ribavarin.
Up till now 1500 patients have completed treatment.
At present 1500 more patients are currently on treatment.

18. GENDER DISTRIBUTION

19. DEMOGRAPHICAL PROFILE

20. MARITAL STATUS

21. AGE DISTRIBUTION

22. DISTRICT WISE DISTRIBUTION

23. RISK FACTORS

24. SYMPTOMATOLOGY

25. GENOTYPE DISTRIBUTION

26. SIDE EFFECTS

27. % patients negative on HCV RNA report
VIROLOGICAL RESPONSE
Type of report
% patients negative on HCV RNA report
4th week HCV RNA
60%
12th week HCV RNA
92%
End of therapy (24/48 weeks)
96%
Sustained Virological Response (SVR)
90%

28. COMPLIANCE RATE Therapy adherence n % Total enrolled patients 1500
100%
Total adherent among all enrolled patients
1402
93.46%
Total non-adherent among all enrolled patients 98
6.54%

29. HEPATITIS C HELPLINE

30. CHEER LEADERS

31. CHEER COUPLE

32. ACTIVE ROLE OF NGO’S

35. AWARENESS BY STAFF

36. MOTIVATION FROM TOP

37. SOFOSBUVIR- A NEW HOPE
Up till now 200 patients have been put on treatment
Majority are on Triple therapy
Dual therapy – Decompensated cirrhotic or on patient will
RVR has been achieved in 95% of patients
Excellent Compliance rate

38. CONCLUSIONS
Haryana has become new hub of Chronic hepatitis C in India.
Majority of patients are male and belong to young age group i.e years of age group.
Genotype 3 most common and Genotype 4 is more common in comparison to other parts of Northern India.
Most common side effects- A.N. & Depression, Dyspepsia, Weight loss, Malaise, Generalized weakness.
Good compliance and success rates are being achieved.

39. TAKE HOME MESSAGE
Most important and first step is appreciation of problem.
Next step is to prioritize resources in more prevalent areas.
Development of Vaccine and Interferon free regimen is future dream for hepatitis C.
Regular Screening camps and awareness in society is utmost need of hour to curb the menace of this disease.
Do not wait till all resources are compiled- Start moving.

41. RATIONALE BASED TREATMENT
Pseudo belief on Alternative Medicines.
Anti HCV Vs HCV RNA based

42. ECONOMICAL TREATMENT STRATEGIES
SCIENTIFIC AND RATIONALE BASED TREATMENT
ROLE OF TREATING PHYSICIANS
ROLE OF STATE AND CENTER
ROLE OF NGO’S
ROLE OF PHARMACEUTICAL COMPANIES
ROLE OF MEDIA AND GENERAL POPULATION

44. Hepatitis– 2016 Website: hepatitis.omicsgroup.com
Meet the eminent gathering once again at Hepatitis-2016 Dubai, UAE October , 2016
Hepatitis– 2016 Website:
hepatitis.omicsgroup.com